Endothelin-1 is increased in the plasma of patients hospitalised with Covid-19

J Mol Cell Cardiol. 2022 Jun;167:92-96. doi: 10.1016/j.yjmcc.2022.03.007. Epub 2022 Mar 23.

Abstract

Virus induced endothelial dysregulation is a well-recognised feature of severe Covid-19 infection. Endothelin-1 (ET-1) is the most highly expressed peptide in endothelial cells and a potent vasoconstrictor, thus representing a potential therapeutic target. ET-1 plasma levels were measured in a cohort of 194 Covid-19 patients stratified according to the clinical severity of their illness. Hospitalised patients, including those who died and those developing acute myocardial or kidney injury, had significantly elevated ET-1 plasma levels during the acute phase of infection. The results support the hypothesis that endothelin receptor antagonists may provide clinical benefit for certain Covid-19 patients.

Keywords: Covid-19; Endotheliitis; Endothelin receptor antagonists; Endothelin-1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19*
  • Endothelial Cells
  • Endothelin Receptor Antagonists
  • Endothelin-1*
  • Humans
  • Receptor, Endothelin A
  • Receptors, Endothelin
  • Vasoconstrictor Agents

Substances

  • Endothelin Receptor Antagonists
  • Endothelin-1
  • Receptor, Endothelin A
  • Receptors, Endothelin
  • Vasoconstrictor Agents